Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 60

1.

Vascular ventricular coupling in patients with malignant phase hypertension: the West Birmingham malignant hypertension project.

Shantsila A, Dwivedi G, Shantsila E, Steeds RP, Beevers G, Lip GY.

Hypertens Res. 2012 Jul;35(7):725-8. doi: 10.1038/hr.2012.18. Epub 2012 Feb 23.

PMID:
22357519
2.

Beyond Texas City: the state of process safety in the unionized U.S. oil refining industry.

McQuiston TH, Lippin TM, Bradley-Bull K, Anderson J, Beach J, Beevers G, Frederick RJ, Frederick J, Greene T, Hoffman T, Lefton J, Nibarger K, Renner P, Ricks B, Seymour T, Taylor R, Wright M.

New Solut. 2009;19(3):271-88. doi: 10.2190/NS.19.3.a.

PMID:
19778828
3.

Effects of losartan compared with atenolol on lipids in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint reduction in hypertension study.

Olsen MH, Wachtell K, Beevers G, Dahlöf B, de Simone G, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Lyle PA, Nieminen MS, Omvik P, Oparil S, Wedel H.

J Hypertens. 2009 Mar;27(3):567-74. doi: 10.1097/HJH.0b013e32831daf96.

PMID:
19262226
4.

Calciphylaxis associated with widespread pulmonary calcification.

Dhanjal TS, Babu SB, Beevers G, Ferner RE.

BMJ Case Rep. 2009;2009. pii: bcr09.2008.0880. doi: 10.1136/bcr.09.2008.0880. Epub 2009 Mar 20.

5.

Prognostic importance of hemoglobin in hypertensive patients with electrocardiographic left ventricular hypertrophy: the Losartan Intervention For End point reduction in hypertension (LIFE) study.

Olsen MH, Wachtell K, Beevers G, Dahlöf B, Devereux RB, de Faire U, Fyhrquist F, Ibsen H, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Narayan P, Nieminen MS, Omvik P, Oparil S, Wedel H.

Am Heart J. 2009 Jan;157(1):177-84. doi: 10.1016/j.ahj.2008.08.011. Epub 2008 Oct 17.

PMID:
19081416
6.

The Anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes.

Ostergren J, Poulter NR, Sever PS, Dahlöf B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E; ASCOT investigators.

J Hypertens. 2008 Nov;26(11):2103-11. doi: 10.1097/HJH.0b013e328310e0d9.

PMID:
18854748
7.

The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure.

Sever PS, Poulter NR, Dahlof B, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes G, Mehlsen J, Nieminen MS, O'Brien ET, Ostergren J; ASCOT Investigators.

Eur Heart J. 2008 Feb;29(4):499-508. doi: 10.1093/eurheartj/ehm583. Epub 2008 Jan 5.

PMID:
18175773
8.

Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial.

Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen S, Kristinsson A, McInnes G, Mehlsen J, Nieminem M, O'Brien E, Ostergren J; ASCOT Steering Committee Members.

Eur Heart J. 2006 Dec;27(24):2982-8. Epub 2006 Dec 4. Erratum in: Eur Heart J. 2007 Jan;28(1):142.

PMID:
17145722
9.

Clinical trials in hypertension.

Messerli FH, Beevers G, Franklin SS, Pickering TG.

JAMA. 2006 Sep 27;296(12):1463; author reply 1464-5. No abstract available.

PMID:
17003392
10.

Quantification of topological changes in retinal vascular architecture in essential and malignant hypertension.

Hughes AD, Martinez-Perez E, Jabbar AS, Hassan A, Witt NW, Mistry PD, Chapman N, Stanton AV, Beevers G, Pedrinelli R, Parker KH, Thom SA.

J Hypertens. 2006 May;24(5):889-94.

PMID:
16612251
11.

Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).

Sever PS, Poulter NR, Dahlöf B, Wedel H, Collins R, Beevers G, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J.

Diabetes Care. 2005 May;28(5):1151-7.

PMID:
15855581
12.

Body build and risk of cardiovascular events in hypertension and left ventricular hypertrophy: the LIFE (Losartan Intervention For Endpoint reduction in hypertension) study.

de Simone G, Wachtell K, Palmieri V, Hille DA, Beevers G, Dahlöf B, de Faire U, Fyhrquist F, Ibsen H, Julius S, Kjeldsen SE, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Devereux RB.

Circulation. 2005 Apr 19;111(15):1924-31.

13.

Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension.

Karalis I, Beevers G, Beevers M, Lip G.

Blood Press. 2005;14(1):38-44.

PMID:
15823946
14.

Pulse pressure and effects of losartan or atenolol in patients with hypertension and left ventricular hypertrophy.

Fyhrquist F, Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Hille DA, Lyle PA, Edelman JM, Snapinn SM, Wedel H; LIFE Study Group.

Hypertension. 2005 Apr;45(4):580-5.

15.

The effects of losartan compared to atenolol on stroke in patients with isolated systolic hypertension and left ventricular hypertrophy. The LIFE study.

Kjeldsen SE, Lyle PA, Kizer JR, Dahlöf B, Devereux RB, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Snapinn SM, Harris KE, Wedel H; LIFE Study Group.

J Clin Hypertens (Greenwich). 2005 Mar;7(3):152-8.

16.

Losartan benefits over atenolol in non-smoking hypertensive patients with left ventricular hypertrophy: the LIFE study.

Reims HM, Oparil S, Kjeldsen SE, Devereux RB, Julius S, Brady WE, Fyhrquist F, Ibsen H, Lindholm LH, Omvik P, Wedel H, Beevers G, de Faire U, Kristianson K, Lederballe-Pedersen O, Nieminen MS, Dahlöf B; LIFE Study Group.

Blood Press. 2004;13(6):376-84.

PMID:
15771223
17.

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.

Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators.

Drugs. 2004;64 Suppl 2:43-60.

PMID:
15765890
18.

CHHIPS (Controlling Hypertension and Hypotension Immediately Post-Stroke) Pilot Trial: rationale and design.

Potter J, Robinson T, Ford G, James M, Jenkins D, Mistri A, Bulpitt C, Drummond A, Jagger C, Knight J, Markus H, Beevers G, Dewey M, Lees K, Moore A, Paul S; CHHIPS Trial Group.

J Hypertens. 2005 Mar;23(3):649-55. Review.

PMID:
15716709
19.

Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study.

Kizer JR, Dahlöf B, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H, Wachtell K, Edelman JM, Snapinn SM, Harris KE, Devereux RB.

Hypertension. 2005 Jan;45(1):46-52. Epub 2004 Dec 6.

20.

Alcohol consumption and cardiovascular risk in hypertensives with left ventricular hypertrophy: the LIFE study.

Reims HM, Kjeldsen SE, Brady WE, Dahlöf B, Devereux RB, Julius S, Beevers G, De Faire U, Fyhrquist F, Ibsen H, Kristianson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H.

J Hum Hypertens. 2004 Jun;18(6):381-9.

PMID:
15103313

Supplemental Content

Loading ...
Support Center